Header and Body 2

Problem Addressed

One of the promising ways to improve the responses of cancer immunotherapies is the intratumoral co-administration of STING-agonists to stimulate an innate immune response. The current dose regimen requires multiple injections of STING-agonists over the course of months, which demands frequent hospital visits and results in low compliance rates. Additionally, with every injection comes the increasing risks of acquiring hospital infections and stimulating metastasis, as shots are administered at local tumor sites and can perturb vascular networks and the tumor microenvironment. Our technology eliminates these problems by administering a single dose of programmable polymer-based microparticles that can release STING-agonists (or other therapeutic agents) at the site of injection in short, timed-release pulses over the course of months with essentially no leakage between pulses.